Soluble B-Cell Maturation Antigen As a Disease Biomarker in Relapsed or Refractory Multiple Myeloma (RRMM): Evaluation from Elranatamab (ELRA) Magnetismm Studies

被引：5
|
作者：
Elmeliegy, Mohamed [1 ]
Lon, Hoi Kei [1 ]
Wang, Diane [1 ]
Ma, Wei An [1 ]
King, Lindsay [2 ]
Viqueira, Andrea [3 ]
Czibere, Akos [2 ]
机构：
[1] Pfizer, San Diego, CA USA
[2] Pfizer Inc, Cambridge, MA USA
[3] Pfizer SLU, Madrid 28108, Spain
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-190341
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Efficacy and Safety of Elranatamab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) and Prior B-Cell Maturation Antigen (BCMA)-Directed Therapies: Pooled Analysis From MagnetisMM Studies
    Nooka, Ajay K.
    Lesokhin, Alexander M.
    Mohty, Mohamad
    Niesvizky, Ruben
    Maisel, Christopher
    Arnulf, Bertrand
    Larson, Sarah M.
    Varshavsky-Yanovsky, Asya Nina
    Leleu, Xavier
    Karlin, Lionel
    Vesole, David H.
    Bahlis, Nizar J.
    Fernandez de Larrea, Carlos
    Raje, Noopur
    Leip, Eric
    Conte, Umberto
    Elmeliegy, Mohamed
    Viqueira, Andrea
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S496 - S497
  • [2] Efficacy and safety of elranatamab in pts with relapsed/ refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: a pooled analysis from MagnetisMM studies
    Raab, M. S.
    Hanel, M.
    Nooka, A. K.
    Lesokhin, A. M.
    Mohty, M.
    Niesvizky, R.
    Maisel, C.
    Arnulf, B.
    Larson, S. M.
    Varshavsky-Yanovsky, A. N.
    Leleu, X.
    Karlin, L.
    Vesole, D. H.
    Bahlis, N. J.
    de larrea, Fernandez C.
    Raje, N.
    Leip, E.
    Conte, U.
    Elmeliegy, M.
    Viqueira, A.
    Manier, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 232 - 232
  • [3] Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: A pooled analysis from MagnetisMM studies.
    Nooka, Ajay K.
    Lesokhin, Alexander M.
    Mohty, Mohamad
    Niesvizky, Ruben
    Maisel, Christopher
    Arnulf, Bertrand
    Larson, Sarah Marie
    Yanovsky, Asya Varshavsky
    Leleu, Xavier P.
    Karlin, Lionel
    Vesole, David H.
    Bahlis, Nizar J.
    de Larrea, Carlos Fernandez
    Raje, Noopur S.
    Leip, Eric
    Conte, Umberto
    Elmeliegy, Mohamed
    Viqueira, Andrea
    Manier, Salomon
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [4] Pooled Analysis of MagnetisMM Studies: Efficacy and Safety of Elranatamab in Patients with Relapsed or Refractory Multiple Myeloma (RRMM) Previously Exposed to B-cell Maturation Antigen (BCMA)-Directed Therapies
    Ajay, Nooka K.
    Alexander, Lesokhin M.
    Mahamad, Mohty
    Ruben, Niesvizky
    Christopher, Maisel
    Bertrand, Arnulf
    Sarah, Larson M.
    Nina, Asya Varshavsky-Yanovsky
    Xavier, Leleu
    Lionel, Karlin
    David, Vesole H.
    Nizar, Bahlis J.
    de Larrea Carlos, Fernandez
    Noopur, Raje
    Eric, Leip
    Umbarto, Conte
    Mohamed, Elmeliegy
    Andrea, Viqueira
    Saloman, Manier
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 : S27 - S28
  • [5] Efficacy and safety of elranatamab in Japanese patients with relapsed/refractory multiple myeloma (RRMM): a pooled analysis from the MagnetisMM studies
    Ishida, Tadao
    Yokoyama, Hisayuki
    Suzuki, Kenshi
    Ito, Satoshi
    Nagai, Yuya
    Handa, Hiroshi
    Ito, Shigeki
    Kamei, Yoichi
    Nakamura, Masatoshi
    Viqueira, Andrea
    White, Jane Liang
    Take, Kazumi
    Moribe, Toyoki
    Iida, Shinsuke
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S186 - S187
  • [6] Efficacy and Safety of Elranatamab in Black Patients with Relapsed/Refractory Multiple Myeloma (RRMM): A Subgroup Analysis of the Magnetismm Studies
    Varshavsky-Yanovsky, Asya
    Jethava, Yogesh
    Stevens, Don A.
    Nooka, Ajay K.
    Stiff, Patrick J.
    Perez-Cruz, Isabel
    Leip, Eric
    Lesokhin, Alexander
    BLOOD, 2023, 142
  • [7] Elranatamab, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, for Patients With Relapsed/ Refractory Multiple Myeloma (RRMM): Extended Follow-Up and Biweekly Administration From the MagnetisMM-3 Study
    Mohty, Mohamad
    Tomasson, Michael H.
    Arnulf, Bertrand
    Bahlis, Nizar J.
    Prince, H. Miles
    Niesvizky, Ruben
    Rodriguez-Otero, Paula
    Martinez-Lopez, Joaquin
    Koehne, Guenther
    Jethava, Yogesh
    Gabayan, Afshin E.
    Stevens, Don A.
    Nooka, Ajay K.
    Raje, Noopur
    Iida, Shinsuke
    Leip, Eric
    Conte, Umberto
    Czibere, Akos
    Viqueira, Andrea
    Lesokhin, Alexander M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S493 - S494
  • [8] Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients (pts) with relapsed/refractory multiple myeloma (RRMM): extended follow up and biweekly administration from the MagnetisMM-3 study
    Raab, M. S.
    Haenel, M.
    Mohty, M.
    Tomasson, M. H.
    Arnulf, B.
    Bahlis, N. J.
    Prince, H. M.
    Niesvizky, R.
    Rodriguez-Otero, P.
    Martinez-Lopez, J.
    Koehne, G.
    Jethava, Y.
    Gabayan, A. E.
    Stevens, D. A.
    Nooka, A. K.
    Raje, N.
    Iida, S.
    Leip, E.
    Conte, U.
    Czibere, A.
    Viqueira, A.
    Lesokhin, A. M.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 177 - 178
  • [9] Efficacy and Safety of Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma Naive to B-Cell Maturation Antigen (BCMA)-Directed Therapies: Results from Cohort a of the Magnetismm-3 Study
    Bahlis, Nizar Jacques
    Tomasson, Michael H.
    Mohty, Mohamad
    Niesvizky, Ruben
    Nooka, Ajay K.
    Manier, Salomon
    Maisel, Christopher
    Jethava, Yogesh
    Martinez-Lopez, Joaquin
    Prince, H. Miles
    Arnulf, Bertrand
    Rodriguez Otero, Paula
    Koehne, Guenther
    Touzeau, Cyrille
    Raje, Noopur
    Iida, Shinsuke
    Raab, Marc-Steffen
    Leip, Eric
    Sullivan, Sharon
    Conte, Umberto
    Viqueira, Andrea
    Lesokhin, Alexander M.
    BLOOD, 2022, 140
  • [10] Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients (pts) with relapsed/refractory multiple myeloma (RRMM): Extended follow up and biweekly administration from the MagnetisMM-3 study.
    Mohty, Mohamad
    Tomasson, Michael H.
    Arnulf, Bertrand
    Bahlis, Nizar J.
    Prince, H. Miles
    Niesvizky, Ruben
    Rodriguez-Otero, Paula
    Martinez-Lopez, Joaquin
    Koehne, Guenther
    Jethava, Yogesh
    Gabayan, A. Eli
    Stevens, Don A.
    Nooka, Ajay K.
    Raje, Noopur S.
    Iida, Shinsuke
    Leip, Eric
    Conte, Umberto
    Czibere, Akos Gabor
    Viqueira, Andrea
    Lesokhin, Alexander M.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345